Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836173 | 0.84 | CYP2A6 (0.52) | CYP2A6ADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL30253262 | 0.83 | CYP1A2 (0.52) | CYP2A6ADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL9672282 | 0.83 | CYP1A2 (0.52) | CYP2A6ADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL11247615 | 0.78 | — | — | |
| SCHEMBL1861381 | 0.78 | ADRA2A (0.48) | CYP2A6ADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL12430508 | 0.77 | ADRA2A (0.44) | CYP2A6ADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL14220348 | 0.76 | CYP2A6 (0.52) | CYP2A6CYP1A2 | |
| SCHEMBL1662187 | 0.76 | CYP2A6 (0.52) | CYP2A6CYP1A2 | |
| SCHEMBL8061942 | 0.76 | CYP2A6 (0.52) | CYP2A6CYP1A2NOTUM | |
| SCHEMBL7333315 | 0.76 | CYP2A6 (0.52) | CYP2A6CYP1A2AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796702-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9790200-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170226085-A1 | DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226079-A1 | DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| EP-0817767-A1 | BICYCLIC AMINE DERIVATIVES AND THEIR USE AS ANTI-PSYCHOTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030333-A1 | BICYCLIC AMINE DERIVATIVES AND THEIR USE AS ANTI-PSYCHOTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-10-03 | — | — | WO | disclosed |
| EP-0230967-B1 | BENZAZECINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-10-23 | — | — | EP | disclosed |
| CN-1013111-B | The method for preparing Benzazecin derivative | HOFFMANN LA ROCHE (CH) | 1991-07-10 | — | — | CN | disclosed |
| US-4957911-A | LEARNING ENHANCEMENT | HOFFMANN-LA ROCHE INC. (US) | 1990-09-18 | — | — | US | disclosed |
| US-4876340-A | Benzazecine derivatives for cognitive and memory functions | HOFFMANN-LA ROCHE INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4749791-A | Benzo[f]quinoline intermediates | HOFFMANN-LA ROCHE INC. (US) | 1988-06-07 | — | — | US | disclosed |
| US-4732979-A | CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1988-03-22 | — | — | US | disclosed |
| CN-87100312-A | Benzacyclodecane derivatives | — | 1987-09-09 | — | — | CN | disclosed |
| EP-0230967-A2 | Benzazecine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | RECQL, NDUFS5, NDUFS7 | CYP2A6 1806/4885ADRA2A 1431/4885ADRA2B 1130/4885 |
| US-20170226085-A1 | DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | QDPR, RECQL, RDX | CYP2A6 1550/4885ADRA2A 1646/4885ADRA2B 1226/4885 |
| US-20170226079-A1 | DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | QDPR, RECQL, NDUFS5 | CYP2A6 1181/4885ADRA2A 1888/4885ADRA2B 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.